YMAB - Y-mAbs Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

277.9M

Cash

92.63M

Avg Qtr Burn

-16.03M

Short % of Float

4.96%

Insider Ownership

12.34%

Institutional Own.

61.81%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DANYELZA® (naxitamab-gqgk) Details Spinal cord tumor, Neuroblastoma, Spinal cord injury, Cancer, Osteosarcoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Omburtamab (monoclonal antibody 8H9 (131I-8H9)) Details Brain tumor, Spinal cord tumor	BLA FDA meeting	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Naxitamab + GM-CSF Details Cancer, Neuroblastoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GD2-SADA Details Cancer, Solid tumor/s, Melanoma, Small cell lung cancer, Sarcoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GD2-GD3 Vaccine Details Rare diseases, Spinal cord tumor, Neuroblastoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.